Skip to main content
Top
Published in: Angiogenesis 2/2012

01-06-2012 | Original Paper

VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients

Authors: Jon E. Peterson, David Zurakowski, Joseph E. Italiano Jr, Lea V. Michel, Susan Connors, Marsha Oenick, Robert J. D’Amato, Giannoula L. Klement, Judah Folkman

Published in: Angiogenesis | Issue 2/2012

Login to get access

Abstract

Platelets sequester angiogenesis regulatory proteins which suggests an avenue for developing biomarkers to monitor disease. We describe a comparison of angiogenesis regulatory proteins found in platelets of colorectal cancer patients and normal controls. Platelet and plasma content of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), platelet derived growth factor (PDGF), platelet factor 4 (PF4), thrombospondin-1 (TSP-1) and endostatin in 35 patients with colon cancer were compared with 84 age-matched healthy controls using ELISAs. We standardized the platelet preparation procedure, introduced process controls and normalized the respective protein levels to platelet numbers using an actin ELISA. Statistically significant differences were found in the median levels of VEGF, PF4 and PDGF in platelets of patients with cancer compared to healthy individuals. Platelet concentrations in cancer patients versus controls were: VEGF 1.3 versus 0.6 pg/106, PF4 18.5 versus 9.4 ng/106, and PDGF 34.1 versus 21.0 pg/106. Multivariable logistic regression analysis indicated that PDGF, PF4 and VEGF were independent predictors of colorectal carcinoma and as a set provided statistically significant discrimination (area under the curve = 0.893, P < .0001). No significant differences were detected for bFGF, endostatin, or TSP-1. Reference Change Value analysis determined that the differences seen were not clinically significant. Plasma levels yielded no correlations.
Literature
2.
go back to reference Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6:273–287PubMedCrossRef Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6:273–287PubMedCrossRef
3.
go back to reference Fuhrmann-Benzakein E, Ma MN, Rubbia-Brandt L et al (2000) Elevated levels of angiogenic cytokines in the plasma of cancer patients. Int J Cancer 85:40–45PubMedCrossRef Fuhrmann-Benzakein E, Ma MN, Rubbia-Brandt L et al (2000) Elevated levels of angiogenic cytokines in the plasma of cancer patients. Int J Cancer 85:40–45PubMedCrossRef
5.
go back to reference Peterson JE, Zurakowski D, Italiano JE Jr et al (2010) Normal ranges of angiogenesis regulatory proteins in human platelets. Amer. J. Hematology 85:487–493CrossRef Peterson JE, Zurakowski D, Italiano JE Jr et al (2010) Normal ranges of angiogenesis regulatory proteins in human platelets. Amer. J. Hematology 85:487–493CrossRef
6.
go back to reference Klement GL, Kikuchi L, Kieran M (2004) Early tumor detection using platelet uptake of angiogenesis regulators. Blood 104 (abstr 839) Klement GL, Kikuchi L, Kieran M (2004) Early tumor detection using platelet uptake of angiogenesis regulators. Blood 104 (abstr 839)
7.
go back to reference Klement GL, Yip T–T, Cassiola F et al (2009) Platelets actively sequester angiogenesis regulators. Blood 113:2835–2842PubMedCrossRef Klement GL, Yip T–T, Cassiola F et al (2009) Platelets actively sequester angiogenesis regulators. Blood 113:2835–2842PubMedCrossRef
8.
go back to reference Saldago R, Benoy I, Bogers J et al (2001) Platelets and vascular endothelial growth factor (VEGF): a morphological and functional study. Angiogenesis 4:37–43CrossRef Saldago R, Benoy I, Bogers J et al (2001) Platelets and vascular endothelial growth factor (VEGF): a morphological and functional study. Angiogenesis 4:37–43CrossRef
9.
go back to reference Gonzalez FJ, Rueda A, Sevilla I et al (2004) Shift in the balance between circulating thrombospondin-1 and vascular endothelial growth factor in cancer patients: Relationship to platelet a-granule content and primary activation. Int J Biol Markers 19:221–228PubMed Gonzalez FJ, Rueda A, Sevilla I et al (2004) Shift in the balance between circulating thrombospondin-1 and vascular endothelial growth factor in cancer patients: Relationship to platelet a-granule content and primary activation. Int J Biol Markers 19:221–228PubMed
10.
go back to reference Hartwig JC (2008) The platelet cytoskeleton. In: Gresele P, Fuster V, López JA, Page CP, Vermylen J (eds) Platelets in hematologic and cardiovascular disorders. Cambridge University Press, New York, pp 75–97 Hartwig JC (2008) The platelet cytoskeleton. In: Gresele P, Fuster V, López JA, Page CP, Vermylen J (eds) Platelets in hematologic and cardiovascular disorders. Cambridge University Press, New York, pp 75–97
11.
go back to reference Cervi D, Yip TT, Bhattacharya N et al (2008) Platelet-associated PF4 as a biomarker of early tumor growth. Blood 111:1201–1207PubMedCrossRef Cervi D, Yip TT, Bhattacharya N et al (2008) Platelet-associated PF4 as a biomarker of early tumor growth. Blood 111:1201–1207PubMedCrossRef
12.
go back to reference Fraser CG (2001) Changes in serial results. In: Biological variation: from principals to practice. AACC Press, Washington, DC, pp 67–90 Fraser CG (2001) Changes in serial results. In: Biological variation: from principals to practice. AACC Press, Washington, DC, pp 67–90
13.
go back to reference Grubbs F (1969) Procedures for detecting outlying observations in samples. Technometrics 11:1–21CrossRef Grubbs F (1969) Procedures for detecting outlying observations in samples. Technometrics 11:1–21CrossRef
14.
go back to reference Altman DG (1991) Practical statistics for medical research. Chapman & Hall, Boca Raton, FL, pp 29–47 Altman DG (1991) Practical statistics for medical research. Chapman & Hall, Boca Raton, FL, pp 29–47
15.
go back to reference Pepe MS (2003) The statistical evaluation of medical tests for classification and prediction. Oxford University Press, New York, pp 66–95 Pepe MS (2003) The statistical evaluation of medical tests for classification and prediction. Oxford University Press, New York, pp 66–95
16.
go back to reference Katz MH (2006) Multivariable analysis: a practical guide for clinicians, 2nd edn. Cambridge University Press, New York, pp 96–136 Katz MH (2006) Multivariable analysis: a practical guide for clinicians, 2nd edn. Cambridge University Press, New York, pp 96–136
17.
go back to reference Zaslavsky A, Baek K-H, Lynch RC et al (2010) Platelet-derived thrombospondin-1 (TSP-1) is a critical negative regulator and potential biomarker of angiogenesis. Blood 115:4605–4613PubMedCrossRef Zaslavsky A, Baek K-H, Lynch RC et al (2010) Platelet-derived thrombospondin-1 (TSP-1) is a critical negative regulator and potential biomarker of angiogenesis. Blood 115:4605–4613PubMedCrossRef
18.
go back to reference Folkman J, Browder T, Palmblad J (2001) Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost 86:23–33PubMed Folkman J, Browder T, Palmblad J (2001) Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost 86:23–33PubMed
19.
go back to reference George ML, Eccles SA, Tutton MG, Abulafi M, Swift RI (2000) Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: Clinical Evidence of Platelet Scavenging? Clin Cancer Res 6:3147–3152PubMed George ML, Eccles SA, Tutton MG, Abulafi M, Swift RI (2000) Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: Clinical Evidence of Platelet Scavenging? Clin Cancer Res 6:3147–3152PubMed
20.
go back to reference Åkerblom B, Lindahl TL, Larsson A (2002) ADP activation induces bFGF binding to platelets in vitro. Upsala J Med Sci 107:165–171PubMedCrossRef Åkerblom B, Lindahl TL, Larsson A (2002) ADP activation induces bFGF binding to platelets in vitro. Upsala J Med Sci 107:165–171PubMedCrossRef
21.
go back to reference Salgado R, Vermeulen PB, Benoy I et al (1999) Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients, Brit. J of Cancer 80:892–897CrossRef Salgado R, Vermeulen PB, Benoy I et al (1999) Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients, Brit. J of Cancer 80:892–897CrossRef
22.
go back to reference Gasic GJ, Gasic TB, Stewart CC (1968) Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 61:46–52PubMedCrossRef Gasic GJ, Gasic TB, Stewart CC (1968) Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 61:46–52PubMedCrossRef
23.
go back to reference Pedersen LM, Milman N (1996) Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J 9:1826–1830PubMedCrossRef Pedersen LM, Milman N (1996) Prognostic significance of thrombocytosis in patients with primary lung cancer. Eur Respir J 9:1826–1830PubMedCrossRef
24.
go back to reference Ikeda M, Furukawa H, Imamura H et al (2002) Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 9:287–291PubMedCrossRef Ikeda M, Furukawa H, Imamura H et al (2002) Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 9:287–291PubMedCrossRef
25.
go back to reference Verheul HM, Hoekman K, Luykx-de Bakker S et al (1997) Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 3:2187–2190PubMed Verheul HM, Hoekman K, Luykx-de Bakker S et al (1997) Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 3:2187–2190PubMed
26.
go back to reference Italiano JE Jr, Richardson JL, Patel-Hett S (2008) Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate alpha granules and differentially released. Blood 111:1227–1233PubMedCrossRef Italiano JE Jr, Richardson JL, Patel-Hett S (2008) Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate alpha granules and differentially released. Blood 111:1227–1233PubMedCrossRef
27.
go back to reference Ma L, Perini R, McKnight W et al (2005) Proteinase activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci USA 102:216–220PubMedCrossRef Ma L, Perini R, McKnight W et al (2005) Proteinase activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci USA 102:216–220PubMedCrossRef
28.
go back to reference Ellis LM, Takahashi Y, Liu W, Shaheen R (2000) Vascular endothelial growth factor in human colon cancer: Biology and therapeutic implications. Oncologist 5(suppl 1):11–15PubMedCrossRef Ellis LM, Takahashi Y, Liu W, Shaheen R (2000) Vascular endothelial growth factor in human colon cancer: Biology and therapeutic implications. Oncologist 5(suppl 1):11–15PubMedCrossRef
30.
go back to reference Lindmark G, Sundberg C, Glimelius B (1993) Stromal expression of platelet-derived growth factor beta-receptor and platelet-derived growth factor B-chain in colorectal cancer. Lab Invest 69(6):682–689PubMed Lindmark G, Sundberg C, Glimelius B (1993) Stromal expression of platelet-derived growth factor beta-receptor and platelet-derived growth factor B-chain in colorectal cancer. Lab Invest 69(6):682–689PubMed
Metadata
Title
VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients
Authors
Jon E. Peterson
David Zurakowski
Joseph E. Italiano Jr
Lea V. Michel
Susan Connors
Marsha Oenick
Robert J. D’Amato
Giannoula L. Klement
Judah Folkman
Publication date
01-06-2012
Publisher
Springer Netherlands
Published in
Angiogenesis / Issue 2/2012
Print ISSN: 0969-6970
Electronic ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-012-9259-z

Other articles of this Issue 2/2012

Angiogenesis 2/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.